Fierce Biotech April 30, 2024
GSK and Genomics plc will collaborate on a new precision medicine initiative that assesses how genetic data can be used in clinical trial design, Genomics announced April 30.
The project will look at ways Genomics’ technology for utilizing polygenic risk scores (PRS)—a way to assess how likely a person is to develop a disease or respond to a drug based on their genes—can be used to understand disease risk and inform patient selection for clinical trials. GSK and Genomics will see whether they can use the tools to reduce the number of trial participants, shorten the duration of a study and improve trial outcomes.
“PRS-based approaches have the potential to...
Today's Sponsors
Today's Sponsor